Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.
University of Copenhagen, Department of Nutrition, Exercise and Sports, Faculty of Science, Copenhagen, Denmark.
Am J Clin Nutr. 2019 Apr 1;109(4):1029-1037. doi: 10.1093/ajcn/nqy363.
Several studies recently reported contradicting results regarding the link between amylase 1 (AMY1) copy numbers (CNs), obesity, and type 2 diabetes.
The aim of this study was to assess the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-phase dietary weight loss intervention.
Using the paralog ratio test, AMY1 CNs were accurately measured in 761 obese individuals from the DiOGenes study. Subjects first underwent an 8-wk low-calorie diet (LCD, at 800 kcal/d) and then were randomly assigned to a 6-mo weight maintenance dietary (WMD) intervention with arms having different glycemic loads.
At baseline, a modest association between AMY1 CN and BMI (P = 0.04) was observed. AMY1 CN was not associated with baseline glycemic variables. In addition, AMY1 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD. Interaction analyses between AMY1 CN and nutrient intake did not reveal any significant association with clinical parameters (at baseline and following LCD or WMD) or when testing gene × WMD interactions during the WMD phase.
In the absence of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects. This trial was registered at www.clinicaltrials.gov as NCT00390637.
最近有几项研究报告称，在淀粉酶 1（AMY1）拷贝数（CN）、肥胖和 2 型糖尿病之间的联系方面存在相互矛盾的结果。
本研究旨在评估 AMY1 CN 对肥胖个体在 2 阶段饮食减肥干预后的人体测量和血糖结果的影响。
使用等位基因比例测试，在 DiOGenes 研究中的 761 名肥胖个体中准确测量了 AMY1 CN。受试者首先接受 8 周的低热量饮食（LCD，每天 800 卡路里），然后随机分配到 6 个月的维持饮食（WMD）干预，分为不同血糖负荷的两组。
在基线时，观察到 AMY1 CN 与 BMI 之间存在适度的关联（P=0.04）。AMY1 CN 与基线血糖变量无关。此外，在 LCD 或 WMD 后，AMY1 CN 与人体测量或血糖结果均无关。AMY1 CN 与营养素摄入之间的交互分析并未显示与临床参数（基线和 LCD 或 WMD 后）或在 WMD 阶段测试基因×WMD 相互作用时存在任何显著关联。
在与体重轨迹或血糖改善无关的情况下，AMY1 CN 不能被视为超重/肥胖受试者对临床减肥和体重维持计划反应的重要生物标志物。该试验在 www.clinicaltrials.gov 上注册为 NCT00390637。
